331 related articles for article (PubMed ID: 10421612)
1. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
3. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
Dresser GK; Bailey DG; Leake BF; Schwarz UI; Dawson PA; Freeman DJ; Kim RB
Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753
[TBL] [Abstract][Full Text] [Related]
4. Intestinal drug transporter expression and the impact of grapefruit juice in humans.
Glaeser H; Bailey DG; Dresser GK; Gregor JC; Schwarz UI; McGrath JS; Jolicoeur E; Lee W; Leake BF; Tirona RG; Kim RB
Clin Pharmacol Ther; 2007 Mar; 81(3):362-70. PubMed ID: 17215845
[TBL] [Abstract][Full Text] [Related]
5. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
[TBL] [Abstract][Full Text] [Related]
6. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
7. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide.
Tong Y; Zhang R; Ngo SN; Davey AK
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):685-9. PubMed ID: 16895540
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
9. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
10. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.
Ujie K; Oda M; Kobayashi M; Saitoh H
Int J Pharm; 2008 Sep; 361(1-2):7-11. PubMed ID: 18572335
[TBL] [Abstract][Full Text] [Related]
11. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
12. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
[TBL] [Abstract][Full Text] [Related]
13. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
Garver E; Hugger ED; Shearn SP; Rao A; Dawson PA; Davis CB; Han C
Drug Metab Dispos; 2008 Dec; 36(12):2492-8. PubMed ID: 18755851
[TBL] [Abstract][Full Text] [Related]
14. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
[TBL] [Abstract][Full Text] [Related]
15. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.
Shirasaka Y; Kuraoka E; Spahn-Langguth H; Nakanishi T; Langguth P; Tamai I
J Pharmacol Exp Ther; 2010 Jan; 332(1):181-9. PubMed ID: 19779132
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Tahara H; Kusuhara H; Maeda K; Koepsell H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2006 May; 34(5):743-7. PubMed ID: 16455804
[TBL] [Abstract][Full Text] [Related]
18. Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
Kamath AV; Yao M; Zhang Y; Chong S
J Pharm Sci; 2005 Feb; 94(2):233-9. PubMed ID: 15570603
[TBL] [Abstract][Full Text] [Related]
19. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier.
Ishiguro N; Nozawa T; Tsujihata A; Saito A; Kishimoto W; Yokoyama K; Yotsumoto T; Sakai K; Igarashi T; Tamai I
Drug Metab Dispos; 2004 May; 32(5):519-24. PubMed ID: 15100174
[TBL] [Abstract][Full Text] [Related]
20. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]